Lumosa's LT3001 Shows Functional Improvements in Phase 2 Trials for Acute Ischemic Stroke
核心洞察
Lumosa Therapeutics (搜索) reported positive Phase 2 results for LT3001 (Odatroltide (搜索)), a first-in-class dual-functional therapy that combines safe reperfusion with direct neuroprotection for acute ischemic stroke.
In the LT3001-202 trial, moderate stroke patients with disabling symptoms achieved 8% and 13% improvements in modified Rankin Scale scores of 0-1 and 0-2 respectively compared to placebo.
The drug demonstrated a favorable safety profile with no increase in symptomatic intracranial hemorrhage despite multi-dose administration over 3 days.
Lumosa Therapeutics (搜索) announced positive results from two independent Phase 2 clinical trials evaluating LT3001 (Odatroltide (搜索)), a novel stroke drug that addresses key limitations of current acute ischemic stroke treatments. The data, presented at the International Stroke Conference in New Orleans, demonstrated meaningful functional improvements in patients suffering from disabling acute ischemic stroke who cannot receive standard reperfusion treatments.
Dual Mechanism Shows Promise in Stroke Treatment
LT3001 represents a first-in-class dual-functional therapy that combines safe reperfusion with direct neuroprotection. The novel therapeutic agent enhances endogenous fibrinolysis and scavenges harmful free radicals, targeting both the thrombotic and oxidative components of stroke pathophysiology. This dual mechanism addresses multiple aspects of stroke injury, potentially extending the therapeutic window and broadening patient eligibility beyond traditional approaches that focus solely on clot removal.
Clinical Trial Results Demonstrate Efficacy
The LT3001-202 trial, conducted in China with 297 patients, showed particularly impressive results in moderate stroke patients with disabling symptoms. Patients treated with LT3001 achieved 8% and 13% improvements in modified Rankin Scale (mRS) scores of 0-1 and 0-2 respectively, compared to placebo.
Most remarkably, LT3001 showed improvement in functional outcomes in large artery atherosclerosis (LAA) and mismatch-positive populations. In Study 202, LAA patients (n=169) showed an 11% improvement in mRS 0–2 and a 9% gain in mRS 0–1. Study 205 validated these signals via imaging assisted selection, with mismatch-positive patients achieving a 10% absolute improvement in mRS 0–2.
The complementary LT3001-205 trial, spanning the US, EU, and Taiwan with 88 patients, utilized advanced imaging-assisted patient selection. Despite smaller sample sizes, the trial reinforced LT3001's efficacy signals, with patients showing disabling features achieving mRS 0-1 outcomes more often with LT3001 (27%) compared to placebo (17%).
Safety Profile Supports Continued Development
"Across the two Phase 2 trials, LT3001 demonstrated a favorable safety profile, with no increase in symptomatic intracranial hemorrhage (sICH) despite multi-dose administration over 3 days," said Thomas Devlin, MD, PhD, FSVIN, Director of the CHI Memorial Neuroscience Institute, Professor of Neurology Morehouse School of Medicine and principal investigator of the LT3001-205 study.
Devlin noted that LT3001 showed potential benefit beyond the conventional thrombolytic time window, supporting its use in patients ineligible for IV thrombolysis or endovascular thrombectomy (EVT), a population with high unmet need. The consistency of results across two independent trials, using different selection strategies, strengthens confidence in LT3001's broad applicability.
Addressing Critical Unmet Medical Need
"Despite over five decades of research and thousands of potential drug targets, the development of neuroprotective drugs for conditions like stroke has not resulted in any FDA-approved drugs in the U.S.," said Sheng-Wen Yeh (Mimi) Ph.D., general manager, Lumosa. "While many drugs frequently succeed in preclinical, animal-based studies, they fail to show safety or efficacy in human trials. Our efficacy data with LT3001, spanning diverse patient populations, is exciting and provides direction for our Phase 3 programs."
According to the World Health Organization, stroke is the second leading cause of death for people over the age of 60 with approximately 6 million deaths worldwide per year. Ischemic stroke is most common, occurring in about 85% of all stroke cases. There are 15 million people worldwide who suffer a stroke each year, with 80% of stroke patients left with no other treatment options or without desired outcomes due to limited therapeutic options currently available.
Trial Design and Patient Population
Both Phase 2 trials employed rigorous randomized, placebo-controlled methodologies, evaluating patients within 24 hours of stroke onset and focusing on those with disabling symptoms defined as significant arm or leg motor impairment. This patient population represents a substantial portion of stroke cases where current treatment options remain inadequate. Current reperfusion therapies, while effective, are not suitable for all patients due to timing constraints, contraindications, or anatomical factors.
Next Steps and Regulatory Progress
Lumosa recently received feedback from the U.S. Food and Drug Administration regarding its Phase 3 development plans for LT3001. Based on this feedback, the company aims to accelerate global Phase 3 development of LT3001 and deliver innovative and effective treatment options for stroke patients worldwide. The combined Phase 2 results provide critical clinical evidence supporting the continued development of LT3001 for acute ischemic stroke, with plans for Phase 3 trials to further validate these promising results in larger patient populations.